IP Library Granted Patent US 9,624,520
Granted Patent B2
US 9,624,520 · App. 14/279,085 · Granted Apr 18, 2017

Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,520
App. No.
14/279,085
Granted
Apr 18, 2017
Kind
B2
Abstract

Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.

Claims (23)

1. A process for preparing a protein having the structure of Formula (I):

R 1 -(AA) n -R 2

wherein:

R 1 is H or an amino terminus modification group;

R 2 is OH or a carboxy terminus modification group;

n is an integer from 1 to 5000;

each AA is independently selected from an amino acid residue, a pyrrolysine analogue amino acid residue having the structure of Formula (A-2) and a pyrrolysine analogue amino acid residue having the structure of Formula (B-2);

and

wherein at least one AA is a pyrrolysine analogue amino acid residue having the structure of Formula (A-2) or Formula (B-2);

the process comprising:

biosynthetically generate within a cell an amino acid of Formula (VII) or Formula (VIII):

wherein the cell comprises a pylC gene, and a pylD gene, and the cell is in contact with a growth medium comprising a precursor,

or

wherein the cell comprises a pylB gene, a pylC gene and a pylD gene, and

the cell is in contact with a growth medium comprising a precursor, incorporating the amino acid of Formula (VII) or Formula (VIII) into the protein within the cell using an orthogonal tRNA (O-tRNA) and an orthogonal aminoacyl tRNA synthetase (O—RS), wherein the O—RS aminoacylates the O-tRNA with the amino acid of Formula (VII) or Formula (VIII) and the O-tRNA recognize at least one selector codon of a mRNA in the cell,

and

recovering the protein.

2. The process of claim 1 , wherein the cell further comprises a pylS gene and a pylT gene and the amino acid of Formula (VII) or Formula (VIII) is incorporated into the protein within the cell by an aminoacyl tRNA synthetase and a tRNA which recognizes at least one selector codon of a mRNA in the cell, wherein the aminoacyl tRNA synthetase is a gene product of the pylS gene and the tRNA is a gene product of the pylT gene.

3. The process of claim 2 , wherein the selector codon is a TAG amber codon.

4. The process of claim 1 , wherein the precursor is D-ornithine, D-arginine, (2S)-2-amino-6-(2,5-diaminopentanamido)hexanoic acid or (2S)-2-amino-6-((R)-2,5-diaminopentanamido)hexanoic acid.

5. The process of claim 1 , wherein the cell is a prokaryotic cell or a eukaryotic cell.

6. The process of claim 5 , wherein the cell is an Escherichia coli cell, a mammalian cell, a yeast cell or an insect cell.

7. The process of claim 6 , wherein the mammalian cell is a CHO cell, a HeLa cell or a HEK293F cell and the insect cell is a sf9 cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: GEIERSTANGER, BERNHARD; OU, WEIJIA; CELLITTI, SUSAN E.; UNO, TETSUO; CROSSGROVE, TIFFANY; CHIU, HSIEN-PO; HAO, XUESHI; GRUNEWALD, JAN
To: IRM LLC
Reel/Frame 041341/0341 →
MERGER Recorded Apr 16, 2015
From: IRM LLC
To: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
Reel/Frame 035444/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
To: NOVARTIS AG
Reel/Frame 035453/0224 →